¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ O.OPIQ=?:w  
"`WcE/(  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© LEu_RU?  
dZ]['y%  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Y'n+,g  
y$-;6zk\]  
1.Co-stimulators (or co-stimulating molecules) Z]VmTB  
 NW$_w  
2.NK-kB VSf<(udGr  
|t<Uh,Bt  
3.Immunoglobulin superfamily -l)u`f^n|  
xhq-$"B  
4.antigen-presenting cell (APC) |/!3N  
YC,)t71l{  
5.death domain Z@i"/~B|4\  
:U>[*zE4&  
6.CCR and CXCR <d`ksZ+  
9| ('*  
7.Lectin (or mitogen) x~ ;1CB  
S8_>Lw  
8.Clusters of differentiation, CD) ?^f=7e8]  
d<,'9/a>  
9.B7 family 6$.I>8n  
% ]U'   
10.Cytotoxic T lymphocyte, CTL) }={TVs^  
o$Jop"To  
11.IL-15 and IL-15 receptor (IL-15R) WciL zx/  
|O! G[|/3  
12.MHC restriction _{k-&I  
}HLs.k4-;  
13.Affinity-chromatography <meQ  
m ?)k&{I  
14.Cyctosprin A, CsA O_S%PX  
kM JA#{<  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 7A=*3  
aS  $ J `  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© 4DTT/ER'qA  
z&Kh$ $)[  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Z !81\5  
# 9@K  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ 7] }2`^9  
n@PXC8}  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ wV{jJyRl  
@?/>$  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© ~:xR0dqx  
O,_k.EH  
ÃâÒßѧרҵ£º t}X+P`Ovq  
^U.t5jj  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ 9cJ1J7y  
n5z";: p  
Ïû»¯ÄÚ¿Æ£º ;/R\!E   
e9p!Caf~I-  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ {+CBThC  
DPM4v7 S  
ѪҺ²¡Ñ§×¨Òµ£º sD{d8s[(  
QTmMj@R&(  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛÌ³ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»